Summit Therapeutics Inc. (SMMT)
Last Price$19.1(7.5%)
Market Cap$14.6B
SMMT Rating
SMMT Quality rating performance
SMMT Intrinsic Value
Key Highlights:
As of Mar 03, 2025 SMMT Relative Value is $0.5, which is overvalued by 97.2%, compared to current share price of $19.1.
As of Mar 03, 2025 SMMT DCF Value is N/A, which is undervalued by N/A, compared to current share price of $19.1.
SMMT Share Price History
1W 1.5%
1M (4.3%)
6M 51.8%
YTD 624.6%
1Y 327.0%
3Y 566.6%
5Y 1,088.2%
10Y 87.7%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
SMMT Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$14.6B
$14.2B
$0.0
($142.1M)
Shares Outstanding
762M
Employees
200K
Growth (CAGR)
(100.0%)
48.1%
(7.08%)
44.6%
6.78%
Profitability
Intrinsic Value
$0.5 (97.4% overvalued)
N/A
$0.5
($7.2)
($2.7)
(100.0%)
(21.9%)
Valuation (LTM)
Return on Capital
(53.5%)
(47.2%)
(3,335.4%)
(51.1%)
(179.1%)
(1,367.8%)
(1,367.8%)
Financial Health
($405.1M)
2.9x
(24.3x)
Dividends
Earnings
Apr 29, 2025
MISS by 0.0%
MISS by 12.5%
4 Beat & 6 Miss
SMMT Stock Financials
SMMT Income Statement Metrics
Annual
Quarterly
LTM
SMMT Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($142.1M) +85.1% YoY
Capital Expenditure (CAPEX)
($139.0K) +8.5% YoY
Free Cash Flow (FCF)
($142.2M) +84.8% YoY
SMMT Income Statement Overview
Annual
Quarterly
LTM
Jan'16
Jan'17
Jan'18
Jan'19
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Cost of revenue
$15.0M 632.0% YoY
Pre-tax income
$221.3M (64.1%) YoY
0.0% margin
SMMT Balance Sheet Overview
Annual
Quarterly
LTM
Jan'16
Jan'17
Jan'18
Jan'19
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$435.6M
Current assets ($423.8M, 97.3% of total)
$412.3M (94.7%)
$0.0 (0.0%)
Other current assets
$11.4M (2.6%)
Non-current assets ($11.8M, 2.7% of total)
$0.0 (0.0%)
$7,398.0K (1.7%)
$0.0 (0.0%)
Other non-current assets
$4,412.0K (1.0%)
Financial position
($405.1M)
Cash & Short-term
Investments
Total Debt
SMMT Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
SMMT Earnings Surprises
Crunching data... Almost there!
SMMT Dividends
SMMT Dividend Yield
Crunching data... Almost there!
SMMT Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with SMMT
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$14.6B | 5.9 | $0.5 97.4% overvalued | 327.0% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$402.0B | 6.7 | $60.0 32.9% overvalued | (29.6%) | DKK 290.4B | DKK 70.0B | 25.0% | 24.1% | 84.7% | 35.5% | 71.6% | |
$125.5B | 5.7 | $195.0 59.6% overvalued | 14.0% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$74.0B | 6.5 | $1,013.8 48.0% undervalued | (29.5%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 86.7% | 25.0% | 5.7% | |
$38.1B | 5.8 | $109.1 82.5% overvalued | 59.5% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$31.3B | 5.2 | $93.6 61.6% overvalued | 62.3% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$27.1B | 6.3 | $165.8 48.6% undervalued | 24.9% | €3,040.1M | €985.3M | (54.1%) | 32.4% | 84.3% | (41.4%) | 1.3% | |
$15.2B | 5.6 | $179.7 430.9% undervalued | 15.9% | $2,263.9M | $2,769.5M | (3.8%) | 122.3% | 73.9% | 14.5% | 0.0% | |
$14.8B | 5.6 | $46.7 33.6% overvalued | 17.6% | $4,241.2M | $235.2M | 14.8% | 5.5% | 92.3% | (12.7%) | 1.3% | |
$14.0B | 7.7 | $427.2 37.8% undervalued | 35.5% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$1,846.9M | 5.4 | $2,805.1 1,137.3% undervalued | 39.9% | $3,316.8M | ($1,009.2M) | 50.5% | (30.4%) | 83.1% | (38.4%) | 32.1% |
FAQ
What is Summit Therapeutics Inc. (SMMT) stock rating?
As of today, Summit Therapeutics Inc. has a stock rating of 6 (out of 10), which is considered Good.
is Summit Therapeutics Inc. (SMMT) a good stock to buy?
As of today, Summit Therapeutics Inc. has a Good stock rating, which is 97.4% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.